InnoSer News: April 2024
Read more about our preclinical research, general drug development services and updates in our monthly LinkedIn newsletter. Read below about some of our April highlights across our therapeutic areas.
News from InnoSer’s Neurology Labs – Pharmaco-EEG Data
Currently, preclinical neuroscience research calls for more translationally relevant biomarkers that help better predict clinical outcomes. Electrophysiological events recorded via electroencephalography (EEG) recordings, highly utilised in the clinic, arise as translationally relevant biomarkers, not only for clinical but also preclinical research. One such EEG biomarker frequently measured in the clinic is event-related potentials (ERPs).
At InnoSer, we have developed a protocol to test this paradigm using auditory ERP (AERP)-EEG recording, which may be used in rare genetic disease models (Fmr1 KO) or to longitudinally monitor novel investigational drug’s effects and pharmacodynamic efficacy in wild type mice. As part of our April’s newsletter, we showcase validation data from AERP recording in WT mice in response to administration of the GABA-B agonist Baclofen and the anti-seizure medication Fenfluramine.
Visit our website to view the full dataset: https://www.innoserlaboratories.com/newsletter/relevant-pharmaco-eeg-in-vivo-data-baclofen-fenfluramine/
Effect of Salsalate on disease progression in the ADPKD Mouse Model
The cellular energy sensor and regulator AMPK has also received much attention as a putative ADPKD therapeutic strategy via its upstream inhibitory effects on the mTORC1 signaling pathway. Salsalate, a pro-drug dimer of salicylate belonging to the family of NSAIDs, activates AMPK through direct interactions with the drug-binding domain of the AMPK beta-1 isoform. As such, Salsalate arises as a key candidate for drug repurposing in ADPKD.
In this month’s newsletter, in line with previous research, we show that Salsalate (0.25% in food for 10 weeks) reduces kidney weight and blood urea levels in our Pkd1 KO ADPKD mouse model. Therefore, for drug developers focusing on targeting upstream or downstream targets of the AMPK signaling pathway, Salsalate may be a suitable positive control in InnoSer’s ADPKD mouse model.
Visit our website to view the full data set: https://www.innoserlaboratories.com/newsletter/effect-of-salsalate-on-adpkd-progression-in-the-adpkd-mouse-model/
Meet Us – Event Exhibitions
Meet Amandine Boeckx at MEET 2 WIN – Open Innovation in Oncology event taking place on May 16th in Bordeaux, France.
Our InnoSer team consisting of CSO Yanick Fanton, CBO Kris Motmans, business development manager, Charlotte Wuyts, together with our study directors, Jolien Beeken and Céline Erens look forward to meeting you at booth #86!